Boston Scientific Co. (NYSE:BSX) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lowered its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 56.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,400 shares of the medical equipment provider's stock after selling 110,449 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Boston Scientific were worth $7,539,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BSX. Parnassus Investments LLC increased its holdings in shares of Boston Scientific by 0.7% in the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after purchasing an additional 97 shares during the period. Evergreen Capital Management LLC boosted its holdings in shares of Boston Scientific by 1.7% in the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after acquiring an additional 106 shares in the last quarter. PDS Planning Inc increased its stake in shares of Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares during the period. Adero Partners LLC raised its holdings in Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares in the last quarter. Finally, Tradition Wealth Management LLC lifted its position in Boston Scientific by 2.2% in the fourth quarter. Tradition Wealth Management LLC now owns 5,510 shares of the medical equipment provider's stock valued at $492,000 after purchasing an additional 121 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Truist Financial increased their target price on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Morgan Stanley lifted their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Evercore ISI boosted their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. BTIG Research restated a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Argus set a $130.00 price objective on shares of Boston Scientific in a research note on Tuesday, February 18th. Twenty-three analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Buy" and an average target price of $114.52.

Insiders Place Their Bets

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at $1,955,420.70. The trade was a 19.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 307,025 shares of company stock worth $31,742,060 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 0.4 %

Shares of Boston Scientific stock traded up $0.39 during trading hours on Wednesday, hitting $104.51. The company's stock had a trading volume of 1,290,790 shares, compared to its average volume of 6,321,500. The business has a fifty day moving average of $98.71 and a 200 day moving average of $95.66. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $154.57 billion, a PE ratio of 83.57, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period last year, the company posted $0.56 earnings per share. The firm's revenue was up 20.9% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.